MaxCyte, Inc. (AIM:MXCT)
236.80
-3.20 (-1.33%)
Mar 26, 2025, 9:27 AM GMT+1
MaxCyte Revenue
In the year 2024, MaxCyte had annual revenue of $38.63M USD, down -6.44%. MaxCyte had revenue of $8.69M in the quarter ending December 31, 2024, a decrease of -44.51%.
Revenue
$38.63M
Revenue Growth
-6.44%
P/S Ratio
8.16
Revenue / Employee
$338.83K
Employees
114
Market Cap
254.47M GBP
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 38.63M | -2.66M | -6.44% |
Dec 31, 2023 | 41.29M | -2.97M | -6.72% |
Dec 31, 2022 | 44.26M | 10.37M | 30.59% |
Dec 31, 2021 | 33.89M | 7.73M | 29.52% |
Dec 31, 2020 | 26.17M | 4.55M | 21.04% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
AstraZeneca | 43.19B |
GSK plc | 31.38B |
Haleon | 11.23B |
Smith & Nephew | 4.64B |
ConvaTec Group | 1.83B |
Hikma Pharmaceuticals | 2.50B |
HUTCHMED (China) | 503.39M |
Genus | 671.60M |
MaxCyte News
- 10 days ago - MaxCyte: Strong Revenues, Fast-Growing Cell-Therapy Market, Very Low Share Price - Seeking Alpha
- 14 days ago - MaxCyte Inc (MXCT) Q4 2024 Earnings Call Highlights: Strategic Growth Amid Revenue Challenges - GuruFocus
- 14 days ago - Q4 2024 MaxCyte Inc Earnings Call Transcript - GuruFocus
- 14 days ago - MaxCyte, Inc. (MXCT) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 14 days ago - MaxCyte GAAP EPS of -$0.10 beats by $0.03, revenue of $8.7M beats by $0.79M - Seeking Alpha
- 14 days ago - MaxCyte Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Full Year 2025 Guidance - GlobeNewsWire
- 6 weeks ago - MaxCyte, TG Therapeutics sign strategic platform license to advance autoimmune cell therapeutics programs - Seeking Alpha
- 6 weeks ago - MaxCyte Signs Strategic Platform License with TG Therapeutics to Advance its Autoimmune Cell Therapeutics Programs - GlobeNewsWire